<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01312779</url>
  </required_header>
  <id_info>
    <org_study_id>2008-07</org_study_id>
    <nct_id>NCT01312779</nct_id>
  </id_info>
  <brief_title>Magna Mitral - 23mm</brief_title>
  <official_title>Clinical Evaluation of the Size 23mm Carpentier-Edwards PERIMOUNT Magna Mitral Bioprosthesis, Model 7000TFX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to obtain human clinical data that demonstrates that
      the size 23mm Carpentier-Edwards PERIMOUNT Magna mitral pericardial valve, model 7000TFX, is
      a safe and effective replacement heart valve.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, multi-site, descriptive study. A minimum of 15 and up
      to 20 subjects will be implanted at a minimum of 2 and up to 8 participating investigational
      sites within the US and internationally.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean effective orifice area at 1 year post implant</measure>
    <time_frame>Entire study period-5 years post implant</time_frame>
    <description>Mean effective orifice area (EOA) at 1 year post-implant will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subject in NYHA functional class I or II at 1 year post-implant.</measure>
    <time_frame>Entire study period ; 5 years post implant</time_frame>
    <description>The pre-procedure and 1 year post-procedure NYHA distribution (numbers and percentage of subjects) will be tabulated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mitral Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>All subjects receive implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects serve as own control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of CEP Magna Mitral Model 7000TFX</intervention_name>
    <description>Heart valve surgery: CEP Magna Mitral Model 7000 TFX</description>
    <arm_group_label>All subjects receive implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has mitral valve disease requiring surgical replacement

          2. Patient has provided written informed consent prior to mitral valve surgery

          3. Patient is expected to survive surgery and be discharged

          4. Patient is willing to comply with specified follow-up evaluations

          5. Patient is 13 years of age or older

        Exclusion Criteria:

          1. Patient has life expectancy &lt; 12 months due to non-cardiac co-morbid conditions;

          2. Patient has/had active endocarditis within the last 3 months

          3. Patient requires replacement of a native or previously implanted prosthetic,
             tricuspid, pulmonic or aortic valve;

          4. Patient was previously enrolled and implanted in the study

          5. Patient has/had prior aortic, tricuspid and/ or pulmonary valve surgery, which
             included implantation of a bioprosthetic valve or mechanical valve that will remain in
             situ

          6. Patient has a body surface area (BSA) &gt; 1.9m2

          7. Female patients who are pregnant, planning to become pregnant, or lactating

          8. Patient has a documented history of substance ( drug or alcohol) abuse

          9. Patient is currently a prison inmate

         10. Patient is currently participating in an investigational drug or another device study

         11. Patient is undergoing renal dialysis for chronic renal failure or has
             hyperparathyroidism

         12. Patient has active myocarditis

         13. Patient has had an acute preoperative neurological deficit, myocardial infarction, or
             cardiac event and has not returned to baseline or stabilized &gt; 30 days prior to the
             planned v alve implant surgery

         14. Patient has an abnormality such as an aortic aneurysm (e.g. due to cystic medial
             necrosis or Marfan's syndrome), aortic dissection, or ventricular aneurysm that might
             place
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Champion</last_name>
    <role>Study Chair</role>
    <affiliation>Edwards Lifesciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Thomas Health</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The John Paul II Hospital in Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2011</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Valve Replacement</keyword>
  <keyword>23mm CEP</keyword>
  <keyword>Magna</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

